May 31, 2023
AbbVie Japan President James Feliciano After a two-digit revenue dip in 2021, AbbVie Japan returned to growth last year with an uptick of 1%, driven by its immunology stars Skyrizi (risankizumab) and Rinvoq (upadacitinib). President James Feliciano says the company...read more